Oblenio Secures $62 Million in Latest Series B Funding Round

Oblenio secured $62 million in its latest Series B, adding another data point to the Legal, Regulatory & Compliance funding market.

Oblenio Raises $62 million in Funding

Oblenio's $62M series B for trispecific antibody in autoimmune diseases. Based on these robust preclinical data, Oblenio is moving rapidly toward clinical trial initiation.

Investors Behind the Funding

The round was backed by Pfizer Ventures. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Oblenio operates in Legal, Regulatory & Compliance. Oblenio's financing adds to recent private-market activity.

Strategic Use of Funds

Read the full story, subscribe or sign in.

Looking Ahead

Oblenio's $62M series B for trispecific antibody in autoimmune diseases

Source reference: original announcement/article.